ダウンロード数: 2464
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
57_291.pdf | 889.26 kB | Adobe PDF | 見る/開く |
タイトル: | 去勢抵抗性前立腺癌に対するFlutamideを用いたアンチアンドロゲン交替療法 |
その他のタイトル: | Alternative Antiandrogen Therapy with Flutamide in Patients with Castration-Resistant Prostate Cancer : A Single Center Experience |
著者: | 高田, 剛 石津谷, 祐 岡田, 宜之 植田, 知博 井上, 均 原, 恒男 |
著者名の別形: | Takada, Tsuyoshi Ishizuya, You Okada, Takayuki Ueda, Tomohiro Inoue, Hitoshi Hara, Tsuneo |
キーワード: | Castration-resistant prostate cancer Alternative antiandrogen therapy Flutamide |
発行日: | Jun-2011 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 57 |
号: | 6 |
開始ページ: | 291 |
終了ページ: | 295 |
抄録: | Alternative Antiandrogen Therapy with Flutamide in Patients with Castration-Resistant Prostate Cancer : A Single Center Experience We analyzed the clinical effects of flutamide (FLT) as a second-line agent for maximum androgen blockade (MAB) in patients with castration-resistant prostate cancer who received bicalutamide (BCL) as the first-line MAB agent. This study included 44 cases with progressive prostate cancer who had relapsed after first-line MAB, with BCL at 80 mg/day. After checking for antiandrogen withdrawal syndrome (AWS), they were given FLT at 375 mg/day as second-line MAB. A partial response (prostate-specific antigen [PSA] decline ≧50%) and no change (PSA decline of 0-50% or increase <25%) by second-line MAB with FLT were achieved in 34.1% (15/44) and 25.0% (11/44), respectively. The median duration of PSA response was 8.2+/−4.5 months. In multivariate analysis, Gleason score (≦7 vs ≧8), the first-line response (CR vs PR+NC), and the second-line response (PR+NC vs PD) were significantly predictive of cause-specific survival from first-line hormonal therapy relapse to cancer death. Our results confirm previous findings that alternative antiandrogen therapy is effective as a second-line hormonal therapy. |
著作権等: | 許諾条件により本文は2012-07-01に公開 |
URI: | http://hdl.handle.net/2433/143307 |
PubMed ID: | 21795830 |
出現コレクション: | Vol.57 No.6 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。